Screener
BioCryst Pharmaceuticals BCRX Financing Lease, Expense
Financing Lease, Expense at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept bcrx:FinancingLeaseExpense.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating lease expense | $781 | $526 | $1,487 | $1,070 |
| Finance lease expense: | ||||
| Amortization of right of use assets | $366 | $554 | $743 | $1,092 |
| Interest on lease liabilities | 55 | 90 | 119 | 184 |
| Total finance lease expense | $421 | $644 | $862 | $1,276 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's financing lease, expense?
- BioCryst Pharmaceuticals (BCRX) reported financing lease, expense of $421K in Q2 2026.
- How has BioCryst Pharmaceuticals's financing lease, expense changed year-over-year?
- BioCryst Pharmaceuticals's financing lease, expense decreased by 34.6% year-over-year, from $644K to $421K.
- What is the long-term trend for BioCryst Pharmaceuticals's financing lease, expense?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's financing lease, expense has grown at a 106.2% compound annual growth rate (CAGR), from $135K to $2.44M.
- What does financing lease, expense mean?
- Financing Lease, Expense as reported by BioCryst Pharmaceuticals Inc.
Ask your AI about BioCryst Pharmaceuticals's financing lease, expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude